 | | Vol. 15.07 – 27 February, 2024 |
| |
|
|
| Scientists demonstrated that Notch activity was highest in a subset of, GFI1 +, HSC-primed hemogenic endothelium cells, and is gradually lost with HSC maturation.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers identified a subpopulation of NG2+Runx1+ perivascular cells that displayed a sclerotome-derived vascular smooth muscle cell transcriptomic profile.
[Nature Communications] |
|
|
|
| The authors reported that conditional deletion of ferritin heavy chain 1 in the hematopoietic system reduced the number and repopulation capacity of HSCs.
[Leukemia] |
|
|
|
| Scientists established a stable and heritable zebrafish line expressing human E2A-PBX1 (hE2APBX1) for high-throughput drug screening.
[Haematologica] |
|
|
|
| The C-terminal GATA1 undergoes frameshifting translation as a consequence of GATA1 germline mutation.To investigate the specific function and pathogenic mechanism of this mutant, in vitro mutant models of stable re-expression cells were generated.
[Haematologica] |
|
|
|
| Researchers reported two cases of T/myeloid MPAL harboring BCL11B-associated structural variants that activate TLX3 by genome sequencing and transcriptomic analyses.
[British Journal of Haematology] |
|
|
|
| The authors evaluated the efficacy of pre-transplant infusion of rituximab in patients with ABO-incompatibility in improving red blood cell engraftment after HSC transplantation, measured by time to reach transfusion independence.
[Bone Marrow Transplantation] |
|
|
|
| Researchers compared morphology and blood rheology parameters in patients with multiple myeloma and healthy individuals.
[Scientific Reports] |
|
|
|
|
| Investigators uncovered a role for transitory free cytoplasmic iron as a rheostat for adult stem cell fate control. They found that hematopoietic stem and multipotent progenitor cells harbored comparatively small amounts of free iron.
[Cell Stem Cell] |
|
|
|
| The authors review the evidence supporting the role of preleukemic HSCs in different types of blood cancers, as well as present the alternative models of malignant evolution.
[Frontiers in Oncology] |
|
|
|
|
| Immune-Onc Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
[Immune-Onc Therapeutics, Inc.] |
|
|
|
|
| April 14 – 17, 2024
Glasgow, Scotland, United Kingdom |
|
|
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Luxembourg Institute of Health – Strassen, Luxembourg |
|
|
|
| | University of Alberta – Edmonton, Alberta, Canada |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Cyprus Cancer Research Institute – Aglandjia, Cyprus |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
